Altimmune Gross Margin from 2010 to 2024

ALT Stock  USD 10.18  1.29  14.51%   
Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune main balance sheet or income statement drivers, such as Interest Expense of 142.5 K, Selling General Administrative of 13.5 M or Total Revenue of 265.1 K, as well as many exotic indicators such as Dividend Yield of 0.4, Price Book Value Ratio of 3.93 or Price Earnings To Growth Ratio of 0.38. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.
  
This module can also supplement Altimmune's financial leverage analysis and stock options assessment as well as various Altimmune Technical models . Check out the analysis of Altimmune Correlation against competitors.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

About Altimmune Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Altimmune income statement, its balance sheet, and the statement of cash flows. Altimmune investors use historical funamental indicators, such as Altimmune's Gross Margin, to determine how well the company is positioned to perform in the future. Although Altimmune investors may use each financial statement separately, they are all related. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Altimmune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Altimmune Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Altimmune. Please read more on our technical analysis and fundamental analysis pages.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.

Altimmune Investors Sentiment

The influence of Altimmune's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Altimmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Altimmune's public news can be used to forecast risks associated with an investment in Altimmune. The trend in average sentiment can be used to explain how an investor holding Altimmune can time the market purely based on public headlines and social activities around Altimmune. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Altimmune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Altimmune's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Altimmune's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Altimmune.

Altimmune Implied Volatility

    
  140.32  
Altimmune's implied volatility exposes the market's sentiment of Altimmune stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Altimmune's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Altimmune stock will not fluctuate a lot when Altimmune's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altimmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altimmune's short interest history, or implied volatility extrapolated from Altimmune options trading.

Pair Trading with Altimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Altimmune is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Altimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Altimmune Stock. Highlighted below are key reports to facilitate an investment decision about Altimmune Stock:
Check out the analysis of Altimmune Correlation against competitors.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Altimmune Stock analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.54)
Revenue Per Share
0.008
Quarterly Revenue Growth
180
Return On Assets
(0.25)
Return On Equity
(0.47)
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.